BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06136741 (Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis): BVCT ex-ante prediction vs. reported outcome

On 3 Nov 2024, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 24 Jun 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially insufficient (inferior to both dupilumab and upadacitinib).

Clinical Trial

NCTID
NCT06136741
Acronym
REZOLVE-AD
Drug Name
Rezpegaldesleukin (Rezpeg)
Drug MoA
pegylated recombinant protein IL2 agonist
Drug Modality
PEGylated peptide
Drug Class
First-In-Class
Therapeutic Area
Skin and Connective Tissue Diseases
Indication
Moderate to Severe Atopic Dermatitis
Human Patients
396
Sponsor
Nektar Therapeutics
Phase
Phase 2

Prediction of , index 1820

Prospective Prediction
Prediction Index
1820
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit in EASI75 inferior to dupilumab or upadacitinib)
Technical Prediction
FAILURE (statistically maybe significant yet very weak clinical benefit in EASI75 against placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
233 days in advance
Readout Data Interpretation
rezpegaldesleukin achieved 25% placebo-adjusted EASI75 at week 16; inferior to dupilumab nearly 40% placebo-adjusted EASI75 at week 16 (see DOI-10.1056/NEJMoa1610020); and inferior to upadacitinib’s nearly 60% placebo-adjusted EASI75 at week 24 (see add'l link below)
Press Release
Additional Readout Data
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially insufficient (inferior to both dupilumab and upadacitinib)
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)
Phase
Phase 2
Status
Active not recruiting
Enrollment
396
Lead sponsor
Nektar Therapeutics
Conditions
Moderate to Severe Atopic Dermatitis
Interventions
DRUG: Rezpegaldesleukin; DRUG: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2023-11-15
Primary completion
2025-05-06
Completion
2026-12-31
Primary outcomes
  • Mean percent change in the Eczema Area and Severity Index (EASI) from baseline at Week 16 (Week 0 and Week 16)

NCT06136741 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials